Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312509105547/d10q.htm
EXHIBIT 99.1
 |
11755 Wilshire Blvd., 20th Floor Los Angeles, CA 90025 |
News Release
ABRAXIS BIOSCIENCE REPORTS 2009 FIRST QUARTER
FINANCIAL RESULTS
Company Highlights:
| • |
ABRAXANE® Revenue of $71 Million for the First Quarter Since Re-acquiring Exclusive U.S. Marketing Rights |
| • | Company Reports Net Loss for Common Shareholders of $23 Million, or $0.57 Per Share, or Adjusted Net Loss for Common Shareholders of $6 Million, or $0.14 Per Share |
| • | ABRAXANE Data to be Presented at ASCO 2009 Includes Biomarker SPARC Correlative Data and Results of Combination Therapy Trials |
LOS ANGELES, Calif. — May 7, 2009 — Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2009.
As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. As a result, beginning in 2009, the company no longer recognizes deferred revenue related to the original co-promotion agreement.
Net revenue for the first quarter of 2009 was $72.6 million compared with $82.1 million for the first quarter of 2008. Net revenue for the first quarter of 2009 included $0.8 million of recognized deferred revenue compared with $10.2 million for the same period last year. Revenue from sales of ABRAXANE for the first quarter of 2009 was $70.6 million compared with $79.9 million for the same period in 2008, which included recognition of deferred revenue of $9.1 million. Excluding the recognition of deferred revenue, total ABRAXANE revenue for the first quarter of 2009 was $70.6 million compared with $70.8 million for the comparable period in 2008.
(more)
The following information was filed by Abraxis Bioscience, Inc. on Thursday, May 7, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Abraxis Bioscience, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abraxis Bioscience, Inc..
1409012 Quarterly Reports
- 10-Q Quarterly Report August 2010
- 10-Q Quarterly Report May 2010
- 10-Q Quarterly Report November 2009
- 10-Q Quarterly Report August 2009
-
10-Q Quarterly Report May 2009
